[{"id":"512bc437-8615-447e-b7a6-c0b2aaec1db7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03341143","created_at":"2021-01-18T16:30:11.528Z","updated_at":"2025-02-25T16:07:09.549Z","phase":"Phase 2","brief_title":"Fecal Microbiota Transplant (FMT) in Melanoma Patients","source_id_and_acronym":"NCT03341143","lead_sponsor":"Zarour, Hassane, MD","biomarkers":" PD-1","pipe":" | ","alterations":" IFNG expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/19/2018","start_date":" 03/19/2018","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-10-30"},{"id":"0dac6c28-5f40-4201-a77f-12f5b6db8b0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03984578","created_at":"2021-01-18T19:35:49.603Z","updated_at":"2025-02-25T16:09:13.747Z","phase":"Phase 2","brief_title":"Window of Opportunity Study in Colorectal Cancer","source_id_and_acronym":"NCT03984578","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" IFNG","pipe":" | ","alterations":" IFNG expression","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-10-14"},{"id":"dd45a77d-d5a4-4150-b58b-a6b91ace8084","acronym":"","url":"https://clinicaltrials.gov/study/NCT04513028","created_at":"2021-01-18T21:37:49.532Z","updated_at":"2024-07-02T16:35:01.212Z","phase":"","brief_title":"Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma","source_id_and_acronym":"NCT04513028","lead_sponsor":"Kelly McMasters","biomarkers":" IFNG • TNFA • PTPRC • ITGAM","pipe":" | ","alterations":" IFNG expression","tags":["IFNG • TNFA • PTPRC • ITGAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-05-24"},{"id":"5dd0852b-09ac-4c77-9c9c-5c3316f03542","acronym":"PDAC","url":"https://clinicaltrials.gov/study/NCT06199752","created_at":"2024-01-11T16:17:46.224Z","updated_at":"2024-07-02T16:35:23.926Z","phase":"Phase 4","brief_title":"Synergistic Immunomodulatory Effect of Synbiotics Pre and Postoperative Resection of Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT06199752 - PDAC","lead_sponsor":"Theodor Bilharz Research Institute","biomarkers":" CD8 • IFNG • IL6 • IL10","pipe":" | ","alterations":" IFNG expression","tags":["CD8 • IFNG • IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 12/12/2021","start_date":" 12/12/2021","primary_txt":" Primary completion: 04/20/2023","primary_completion_date":" 04/20/2023","study_txt":" Completion: 09/10/2023","study_completion_date":" 09/10/2023","last_update_posted":"2024-01-10"},{"id":"862473ad-449c-4da2-b5b9-bb1e83feeed4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03546829","created_at":"2021-01-18T17:27:44.097Z","updated_at":"2024-07-02T16:35:26.744Z","phase":"Phase 1","brief_title":"Randomized Pilot Trial of Antimicrobial Therapy and Stereotactic Body Radiation Therapy in Early-stage Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03546829","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" IFNG","pipe":" | ","alterations":" IFNG expression","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/24/2018","start_date":" 04/24/2018","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-12-08"},{"id":"e287b7f7-e014-48e2-9282-b4b1f1b1dc60","acronym":"","url":"https://clinicaltrials.gov/study/NCT03513952","created_at":"2021-01-18T17:17:53.265Z","updated_at":"2024-07-02T16:35:26.918Z","phase":"Phase 2","brief_title":"Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma","source_id_and_acronym":"NCT03513952","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • IFNG • CD4","pipe":" | ","alterations":" PD-L1 expression • IFNG expression","tags":["PD-L1 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • CYT107"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 06/05/2019","start_date":" 06/05/2019","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/22/2024","study_completion_date":" 10/22/2024","last_update_posted":"2023-12-06"},{"id":"18ce33fa-306b-4468-a84f-ebb16fbdbfcf","acronym":"IPRICE","url":"https://clinicaltrials.gov/study/NCT05328024","created_at":"2022-04-14T11:53:36.299Z","updated_at":"2024-07-02T16:35:35.988Z","phase":"","brief_title":"Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT05328024 - IPRICE","lead_sponsor":"Institut de cancérologie Strasbourg Europe","biomarkers":" IFNG","pipe":" | ","alterations":" IFNG expression","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/25/2023","start_date":" 08/25/2023","primary_txt":" Primary completion: 08/25/2029","primary_completion_date":" 08/25/2029","study_txt":" Completion: 08/25/2029","study_completion_date":" 08/25/2029","last_update_posted":"2023-09-22"},{"id":"d5870014-be37-4a8f-b38f-acf430db9ed2","acronym":"TIBIOP-LMC","url":"https://clinicaltrials.gov/study/NCT04645706","created_at":"2021-01-19T20:39:33.885Z","updated_at":"2024-07-02T16:35:40.883Z","phase":"","brief_title":"Innate T Cells and TKI Discontinuation","source_id_and_acronym":"NCT04645706 - TIBIOP-LMC","lead_sponsor":"Poitiers University Hospital","biomarkers":" CD8 • IFNG • IL2RA • CCR7 • ITGA4 • PRF1 • B3GAT1 • ISG20","pipe":" | ","alterations":" CD8 expression • IFNG expression","tags":["CD8 • IFNG • IL2RA • CCR7 • ITGA4 • PRF1 • B3GAT1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • IFNG expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-08-04"},{"id":"9ae4eede-f757-4258-926b-cb6caf976257","acronym":"","url":"https://clinicaltrials.gov/study/NCT05967533","created_at":"2023-08-01T16:10:23.357Z","updated_at":"2024-07-02T16:35:41.462Z","phase":"Phase 1","brief_title":"The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors","source_id_and_acronym":"NCT05967533","lead_sponsor":"University of California, Davis","biomarkers":" CD8 • IFNG • IL6 • IL2RA • CD4 • CD69 • IL2 • IL10 • LAMP1 • TGFB1 • FOXP3 • IL17A • ISG20","pipe":" | ","alterations":" IFNG expression","tags":["CD8 • IFNG • IL6 • IL2RA • CD4 • CD69 • IL2 • IL10 • LAMP1 • TGFB1 • FOXP3 • IL17A • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 06/02/2025","primary_completion_date":" 06/02/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-01"},{"id":"76215dca-1eec-417b-b512-773e2b76f61f","acronym":"CAIRE","url":"https://clinicaltrials.gov/study/NCT04705818","created_at":"2021-01-19T20:51:30.021Z","updated_at":"2025-02-25T14:59:38.130Z","phase":"Phase 2","brief_title":"Combining Epigenetic And Immune Therapy to Beat Cancer.","source_id_and_acronym":"NCT04705818 - CAIRE","lead_sponsor":"Institut Bergonié","biomarkers":" MSI • IFNG","pipe":" | ","alterations":" IFNG expression","tags":["MSI • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 07/23/2021","start_date":" 07/23/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-03-01"},{"id":"a8f4389e-834a-4aa3-a7a4-f6955f4bf261","acronym":"","url":"https://clinicaltrials.gov/study/NCT04438564","created_at":"2021-01-18T21:21:58.152Z","updated_at":"2024-07-02T16:35:56.179Z","phase":"","brief_title":"Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients","source_id_and_acronym":"NCT04438564","lead_sponsor":"China Medical University Hospital","biomarkers":" IFNG • TNFA • IL2","pipe":" | ","alterations":" IFNG expression • IL2 expression","tags":["IFNG • TNFA • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression • IL2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 05/18/2020","start_date":" 05/18/2020","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2023-02-08"},{"id":"c59140a0-25cc-462a-8fa0-14d8fcd877e6","acronym":"AuspiCiOus","url":"https://clinicaltrials.gov/study/NCT05177133","created_at":"2022-01-04T13:53:42.957Z","updated_at":"2024-07-02T16:36:03.789Z","phase":"Phase 2","brief_title":"Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)","source_id_and_acronym":"NCT05177133 - AuspiCiOus","lead_sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","biomarkers":" HER-2 • IFNG • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • HER-2 negative • IFNG expression","tags":["HER-2 • IFNG • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • HER-2 negative • IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/05/2021","start_date":" 11/05/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/04/2029","study_completion_date":" 11/04/2029","last_update_posted":"2022-09-16"},{"id":"b5ce9f6f-90bd-4e6c-8af0-4771e28aea48","acronym":"","url":"https://clinicaltrials.gov/study/NCT03021993","created_at":"2021-01-18T14:52:12.866Z","updated_at":"2025-02-25T14:37:08.309Z","phase":"Phase 2","brief_title":"Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer","source_id_and_acronym":"NCT03021993","lead_sponsor":"Medical University of South Carolina","biomarkers":" CD8 • IFNG • CD4 • CD69 • ICOS • IL10 • GZMB • TGFB1 • FOXP3","pipe":" | ","alterations":" CD8 expression • IFNG expression • IL2 expression","tags":["CD8 • IFNG • CD4 • CD69 • ICOS • IL10 • GZMB • TGFB1 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • IFNG expression • IL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/30/2017","start_date":" 05/30/2017","primary_txt":" Primary completion: 11/15/2021","primary_completion_date":" 11/15/2021","study_txt":" Completion: 11/15/2021","study_completion_date":" 11/15/2021","last_update_posted":"2021-12-13"},{"id":"87214a1a-0657-4f26-bb07-79d14ea87235","acronym":"","url":"https://clinicaltrials.gov/study/NCT02340975","created_at":"2021-01-18T11:07:31.997Z","updated_at":"2024-07-02T16:36:44.382Z","phase":"Phase 1b/2","brief_title":"A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma","source_id_and_acronym":"NCT02340975","lead_sponsor":"MedImmune LLC","biomarkers":" PD-L1 • IFNG","pipe":" | ","alterations":" IFNG expression • PD-L1-L","tags":["PD-L1 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression • PD-L1-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 114","initiation":"Initiation: 03/31/2015","start_date":" 03/31/2015","primary_txt":" Primary completion: 04/29/2019","primary_completion_date":" 04/29/2019","study_txt":" Completion: 04/29/2019","study_completion_date":" 04/29/2019","last_update_posted":"2020-06-09"},{"id":"a267fffc-c41f-4e73-8a3d-4e09bc440e5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00920218","created_at":"2021-01-18T03:33:38.300Z","updated_at":"2024-07-02T16:37:15.594Z","phase":"Phase 2","brief_title":"Safety \u0026 Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A","source_id_and_acronym":"NCT00920218","lead_sponsor":"GlaxoSmithKline","biomarkers":" IFNG • TNFA • CD4 • IL2 • CD40LG","pipe":" | ","alterations":" IFNG expression","tags":["IFNG • TNFA • CD4 • IL2 • CD40LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"],"overall_status":"Completed","enrollment":" Enrollment 121","initiation":"Initiation: 07/14/2009","start_date":" 07/14/2009","primary_txt":" Primary completion: 04/26/2011","primary_completion_date":" 04/26/2011","study_txt":" Completion: 03/21/2012","study_completion_date":" 03/21/2012","last_update_posted":"2017-12-12"},{"id":"0e1d2438-d7a1-40a9-9044-e6ea0040e81b","acronym":"DIGHANC","url":"https://clinicaltrials.gov/study/NCT02906800","created_at":"2021-01-18T14:15:44.741Z","updated_at":"2024-07-02T16:37:17.011Z","phase":"Phase 1/2","brief_title":"Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients","source_id_and_acronym":"NCT02906800 - DIGHANC","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" CD8 • IFNG • IL2RA • CD4 • FOXP3 • IL17A • ISG20","pipe":" | ","alterations":" IFNG expression","tags":["CD8 • IFNG • IL2RA • CD4 • FOXP3 • IL17A • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel"],"overall_status":"Unknown status","enrollment":" Enrollment 15","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2017-10-19"},{"id":"29aa657b-4cdb-4635-b035-5f8a828d7e57","acronym":"","url":"https://clinicaltrials.gov/study/NCT00374049","created_at":"2021-01-18T01:17:55.044Z","updated_at":"2024-07-02T16:37:30.693Z","phase":"Phase 1","brief_title":"MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer","source_id_and_acronym":"NCT00374049","lead_sponsor":"Olivera Finn","biomarkers":" IFNG","pipe":" | ","alterations":" IFNG expression","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 06/01/2006","start_date":" 06/01/2006","primary_txt":" Primary completion: 01/01/2008","primary_completion_date":" 01/01/2008","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2016-07-12"}]